Navigation Links
BSP Raises $2.6 Million Dollars From Private Investors
Date:6/17/2008

TEL AVIV, Israel, June 17 /PRNewswire-FirstCall/ -- BSP Ltd., (http://www.bsp.co.il/pressall.asp) an Israeli company which develops and markets systems for non-invasive diagnosis and monitoring of Ischemic Heart Disease, announced that they successfully raised $2.6 million in a private funding round, that included existing shareholders in the company as well as new investors.

BSP developed the HyperQ(TM), a cutting-edge technology that offers highly reliable, low-cost and risk free cardiac monitoring for broad populations and allows, for the first time, effective and accurate testing for Ischemic Heart Disease - the No. 1 killer in the world.

Thousands of patients in Israel, Europe and the US have already been examined by HyperQ(TM) Stress Systems in controlled clinical studies, pilot programs and routine testing. The results have demonstrated the system's high efficiency and unmatched accuracy in the diagnosis of IHD. The HyperQ(TM) system received FDA clearance (510K), as well as the European CE marking.

The company has entered the clinical and commercial phase, during which the HyperQ(TM) Stress System will be integrated in inpatient and outpatient hospital settings, private doctor offices and major research centers.

Further applications on the company's scope; include bedside monitors for ischemic events; devices for cardiac home-care and telemedicine; and the implementation of the HyperQ(TM) technology in implantable cardiac devices.

"The completion of this round reflects our investors' ongoing confidence in our ability to meet our commercial and clinical milestones. This round will enable us to step-up the marketing and business development efforts in the US, and accelerate development of BSP's next application - the HyperQ bedside monitor," said Dr. Amir Beker, CEO of BSP.

Dr. Beker added, "The HyperQ(TM) technology is a revolutionary non-invasive so
'/>"/>

SOURCE BSP - Biological Signal Processing Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
2. Actress and Mom Lori Loughlin Raises Awareness About the Potential Dangers of Drowsy Driving During Allergy Season
3. New Study Raises Questions About Prostate Cancer Therapies Targeting Insulin-Like Growth Factor Receptor
4. Lilly CEO Praises Massachusetts Leadership in Biotech, Urges Policy Prescriptions to Help Ensure States Investment Generates Dividends and Jobs
5. Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance
6. Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%.
7. Edwards Lifesciences Reports Strong First Quarter Results and Raises 2008 Guidance
8. Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook
9. Stemline Therapeutics Raises $12.5 Million
10. Transave, Inc. Raises $35 Million Through Series D Convertible Preferred Stock Financing
11. Pieris Raises EUR 25 M (US$ 38 M) in Series B Financing Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... the most attractive in the emerging European region, mainly ... and increasing government investment in healthcare, according to a ... set to grow at twice the pace of the ... reaching an approximate market value of $43-60 billion by ... Cross provides total healthcare solutions that address the evolving ...
(Date:3/25/2015)... March 25, 2015 Optimal Research, LLC has ... Excellence (ViE) Award "Best Clinical Site or Trial Network". ... Optimal has been selected as a nominee in this ... a "Highly Recommended" distinction in 2014. The ViE awards ... efforts, accomplishments, and positive contributions of companies and individuals ...
(Date:3/25/2015)... IL (PRWEB) March 25, 2015 ... Symmetry® Top-Loading Balances and Analytical Balances to get ... expanded line of weighing balances from the trusted ... Toploading Balances increase your efficiency by providing ... variety of samples. Weighing modes include parts counting, ...
(Date:3/25/2015)... March 25, 2015 An increase of ... in all forms of food nutrients, regulatory changes and ... substantial rise in demand for natural astaxanthin over the ... to ramp up their capacities to satisfy the rising ... and synthetic source astaxanthin (used in nutraceuticals, aqua feed, ...
Breaking Biology Technology:Optimal Research Nominated 2015 Vaccine Industry Excellence (ViE) Award 2New Economical Top-Loading and Analytical Symmetry Balances from Cole-Parmer 2Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at MarketPublishers.com 2
... 23 BioRelix, pioneers in the discovery and ... Dalton Medicinal Chemistry have jointly announced an ... and agreement to discover and develop new therapeutics.Dalton ... the design and synthesis of new classes of ...
... new study examining the aftereffects of a chlorine gas disaster ... insight into what to expect and how to prepare emergency ... potentially deadly gas. The study is now available in the ... Medicine . , "This is one of the largest ...
... 20 Isolagen(TM), Inc. (Amex: ILE ) ... notice from the Amex (the "Exchange") notifying the Company ... the Exchange,s Company Guide (the "Company Guide"). Specifically, the ... are so substantial in relation to its overall operations ...
Cached Biology Technology:BioRelix and Dalton Medicinal Chemistry Expand and Renew Research Agreement to Capitalize on Riboswitches 2New study examines effects of Graniteville, S.C., chlorine gas disaster 2New study examines effects of Graniteville, S.C., chlorine gas disaster 3Isolagen, Inc. Receives Notification Letter from Amex 2Isolagen, Inc. Receives Notification Letter from Amex 3Isolagen, Inc. Receives Notification Letter from Amex 4
(Date:3/17/2015)... MedNet Solutions , a global ... management systems, is pleased to announce that company ... in Clinical Trials Southeast conference – March 24-25 ... forum for MedNet to showcase iMedNet , ... eClinical technology platform. We strongly encourage ...
(Date:3/16/2015)... HANOVER, Germany , March 16, 2015 /PRNewswire/ ... DERMALOG Identification Systems GmbH will present groundbreaking innovations ... Hanover, Germany . ... DERMALOG,s latest biometric innovation is well at ... the next generation e-gate made in ...
(Date:3/12/2015)... , March 12, 2015 ... standardized identity and access management (IAM) solution for ... schedule. With Beta System,s new IAM package, customers ... practices gleaned from multiple IAM implementations across different ... software as well as any necessary services and ...
Breaking Biology News(10 mins):Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2
... found a surprising link between brain iron levels ... ranging from autism to major depression., Appearing in ... Sciences this week, the study by Randy ... of a powerful in silico approach for discovering ...
... Wegener Institute for Polar and Marine Research in ... expedition LOHAFEX". Independent scientific and legal reviews sought ... and the Federal Ministry for the Environment, Nature ... fertilisation experiment LOHAFEX is neither against environmental standards ...
... Drug Administration is reconsidering the use of stimulants to ... to support a University of Houston professor,s theory that ... order. Richard A. Bond, professor of ... (UHCOP), has been investigating whether beta-2 adrenoreceptor antagonist drugs ...
Cached Biology News:Researchers iron out new role for serotonin 2Polarstern expedition 'LOHAFEX' can be conducted 2Polarstern expedition 'LOHAFEX' can be conducted 3New asthma research opposes current drug treatment, says UH prof 2New asthma research opposes current drug treatment, says UH prof 3New asthma research opposes current drug treatment, says UH prof 4
7G10 anti-Fasciclin III...
Rabbit polyclonal to Nck alpha ( Abpromise for all tested applications). entrezGeneID: 4690 SwissProtID: P16333...
Rabbit polyclonal to P5 ( Abpromise for all tested applications). entrezGeneID: 10954 SwissProtID: Q14554...
Rabbit polyclonal to ZA20D3 ( Abpromise for all tested applications). entrezGeneID: 54469 SwissProtID: Q6FIF0...
Biology Products: